Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisReal-time, aptamer-based tracking of circulating therapeutic agents in living animals.Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.Long-term effects of single and combined introductions of antibiotics and bacteriophages on populations of Pseudomonas aeruginosa.Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida?Carprofen pharmacokinetics in plasma and in control and inflamed canine tissue fluid using in vivo ultrafiltration.Pharmacokinetics and distribution in interstitial and pulmonary epithelial lining fluid of danofloxacin in ruminant and preruminant calves.Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?Long-term administration of oral macrolides for acne treatment increases macrolide-resistant Propionibacterium acnes.Glycinated fullerenes for tamoxifen intracellular delivery with improved anticancer activity and pharmacokinetics.Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent.Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of Klebsiella pneumoniae.
P2860
Q26739860-5ABFCA6F-3E63-462D-9B8D-19E258EDE538Q28542435-B9660F86-0834-4462-834C-22E711498F4EQ33570021-B46554F2-9DFC-49A1-B8F2-D96682083204Q35960788-94E010BD-6D76-4B5D-A8F9-0F92148EBE87Q36083619-02898AEA-3844-4ADC-A7A0-300E3588C600Q36289127-D42A8FB3-F795-4AC7-828F-A601AE31DDF2Q36413575-33BBDDD7-0EA6-4F24-9E37-830311A901D2Q36571957-269168C7-CB8D-46BD-A88E-DBFFF1486824Q37538748-52B5A951-3406-4340-8948-E1822CE66B43Q38810304-FED10E98-E617-4BC9-BE4F-E6701E81B0CAQ38895149-E770DE10-7076-4000-8F05-7EEF1786DF8AQ40165457-7B6D0218-6F5F-481B-9F73-72A99DC7697FQ40175191-A6E744AE-F6E8-4F24-BF3F-DF6441AEA3AAQ40211670-ACE45CF1-B025-407A-A79D-F1DFDBA67A74Q40257051-179035B0-F1EE-4437-A710-8324819B6C15Q42359420-1CC7CAFE-F62A-4468-840E-8C032C3DA17AQ44857486-C29EBFCE-BDF0-40DF-A287-68AF4CF96509Q44865829-C630A7DD-33C4-42F0-BB74-78F7AE300A43Q47774021-163E15DA-68BE-483D-8017-A64D1DA3A9DDQ48126615-8DE53A7C-81A9-4BD2-A91D-D8F92A7F4A8CQ51036543-513BF608-CDC5-4AEA-BAC8-2DA330B2E2E6Q52766694-A0FD5569-3B6D-4B70-B739-DA55F95890F6Q53080458-25875573-19CD-4019-941E-9E72E3DC6E75Q55347292-9AF7BEA0-104F-4AC6-AA78-A454990770AF
P2860
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Importance of relating efficac ...... ions for anti-infective agents
@ast
Importance of relating efficac ...... ions for anti-infective agents
@en
Importance of relating efficac ...... ions for anti-infective agents
@nl
type
label
Importance of relating efficac ...... ions for anti-infective agents
@ast
Importance of relating efficac ...... ions for anti-infective agents
@en
Importance of relating efficac ...... ions for anti-infective agents
@nl
prefLabel
Importance of relating efficac ...... ions for anti-infective agents
@ast
Importance of relating efficac ...... ions for anti-infective agents
@en
Importance of relating efficac ...... ions for anti-infective agents
@nl
P2093
P2860
P3181
P356
P1476
Importance of relating efficac ...... ions for anti-infective agents
@en
P2093
D. Gonzalez
H. Derendorf
S. Schmidt
P2860
P304
P3181
P356
10.1128/CMR.00092-12
P407
P577
2013-04-01T00:00:00Z